Immunocore Holdings plc (IMCR): Deutsche Bank Issues Buy Recommendation With 108% Price Potential!

Immunocore Holdings plc (IMCR) is a biopharmaceutical company based in Oxfordshire, UK, that focuses on developing T-cell receptor (TCR)-based therapies. The company has brought to market KIMMTRAK, the world's first approved TCR therapy, which is approved for the treatment of patients with unresectable or metastatic uveal melanoma in the USA, EU, Canada, Australia, and the UK. In favor with experts Deutsche Bank initiated coverage of Immunocore Holdings PLC (IMCR) on May 27 with a Buy rating and a price target of $65. The institution states...